<DOC>
	<DOCNO>NCT00970307</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity GSK Biologicals ' GSK2202083A vaccine co-administered GSK Biologicals ' 10-valent pneumococcal conjugate ( GSK1024850A ) vaccine give three-dose primary vaccination course 2 , 3 4 month age .</brief_summary>
	<brief_title>Immunogenicity Safety Study GSK Biologicals ' GSK2202083A Vaccine Healthy Infants 2 , 3 4 Months Age</brief_title>
	<detailed_description>In accordance local recommend immunisation schedule , subject receive 2 dos GSK Biologicals ' Human Rotavirus Vaccine ( Rotarix ) 2 3 month age .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>A male female infant , include , 8 12 week age time first vaccination . Born gestation period 36 42 week inclusive . Subjects receive one dose hepatitis B vaccination birth per local recommendation . Subjects investigator believe parent ( ) /LAR comply requirement protocol . Written inform consent obtain parent/LAR subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Administration immunoglobulins and/or blood product since birth plan administration study period . Administration vaccine since birth , exception HBV Bacillus CalmetteGuérin , plan administration study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Evidence previous intercurrent diphtheria , tetanus , pertussis , hepatitis B , polio , Hib , pneumococcal and/or MenC disease . History seizures progressive neurological disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History reaction hypersensitivity likely exacerbate component vaccine . Major congenital defect serious chronic illness . The following condition temporary selflimiting , subject may vaccinate condition resolve exclusion criterion meet : • Current febrile illness axillary temperature &gt; = 38.5 ºC moderate severe illness within 24 hour study vaccine administration .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>